Menu
Annual · values202620252024202320222021202020192018201720162015
Gross Margin
Operating Margin-2072.05%-3542.53%-1197.07%-912.04%-2612.53%-3228.82%-1555.41%-494.58%-523.71%
EBITDA Margin-2030.10%-3500.48%-1191.01%-907.99%-2599.16%-3204.98%-1547.15%-490.24%-518.81%
Net Margin-2094.89%-3540.90%-1196.58%-980.33%-2697.75%-3795.86%-1855.81%-549.57%-891.53%
Current Ratio3.853.133.4010.039.957.539.402.2115.132.614.572.10
Quick Ratio3.853.133.4010.039.957.539.402.2115.132.614.572.10
Debt / Equity
ROE-146.36%-261.31%-211.71%-79.86%-61.30%-84.86%-68.70%-269.44%-94.14%-1222.03%-324.31%-1043.50%
ROA-112.92%-181.91%-148.05%-68.71%-53.64%-73.92%-61.36%-150.25%-77.25%-421.47%-190.57%-492.34%
Asset Turnover0.000.030.020.060.060.060.020.230.350.55
Book Value / Share7.253.282.290.731.150.772.720.130.490.080.200.12

Aethlon Medical Inc. is a medical technology company focused on developing immunotherapeutic products for cancer and infectious disease. Its primary platform, the Aethlon Hemopurifier, is designed to reduce cancer-promoting exosomes and circulating viruses through extracorporeal blood filtration. The company’s work centers on clinical-stage solutions that address life- and organ-threatening conditions, with applications that intersect oncology, virology, and critical care medicine. Aethlon Medical serves the broader healthcare market by advancing device-based technologies intended for diagnostic and therapeutic use in severe diseases. Headquartered in San Diego, California, Aethlon Medical Inc. operates as a specialized developer of highly targeted medical treatments within the biotechnology and medical device sectors.